{"preliminary_commentary":{"by_channel":{"x_thread":7,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06061809\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":null,"indication":"recurrent or progressive glioblastoma","name":"QUILT-3.078","nct_id":"NCT06061809","offer":{"currency":"USD","how":"Buy the first edition with create_order on https://mcp.erudio.com/mcp (product \"first_edition\", report \"NCT06061809\", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/quilt-3-078-nct06061809. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"product":"first_edition","size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Phase 2\n\nParticipants will receive N-803 1 mg subcutaneously (SC), PD-L1 t-haNK (\\~2 × 10\\^9 cells/infusion) intravenously (IV), and Bevacizumab (10 mg/kg IV) combination therapy during 28-day cycles on days 1 and 15 of each cycle. Maximum treatment period is 76 weeks, 19 cycles.","label":"Single Arm","type":"EXPERIMENTAL"},{"description":"Phase 2B: Participants will be randomized 1:1 to 1 of 2 experimental arms (Arm A or Arm B). Treatment for all enrolled participants will consist of repeated 8-week cycles for a maximum treatment period of up to 80 weeks (10 cycles).\n\nExperimental Arm (A):\n\nEvery 2 weeks (Days 1, 15, 29, and 43 of an 8-week cycle):\n\nN-803, 1 mg SC Bevacizumab, 10 mg/kg IV Continuous application (≥ 18 hours/day) to the brain: TTFields, 200 kHz","label":"Experiment Treatment Arm A","type":"EXPERIMENTAL"},{"description":"Participants will be randomized 1:1 to 1 of 2 experimental arms (Arm A or Arm B). Treatment for all enrolled participants will consist of repeated 8-week cycles for a maximum treatment period of up to 80 weeks (10 cycles).\n\nEvery 2 weeks (Days 1, 15, 29, and 43 of an 8-week cycle):\n\nPD-L1 t-haNK, 2 × 109 cells per infusion IV NAI, 1 mg SC Bevacizumab, 10 mg/kg IV\n\nPlus - Continuous application (≥ 18 hours/day) to the brain: TTFields, 200 kHz","label":"Experiment Treatment Arm B","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2030-12-31","type":"ESTIMATED"},"conditions":["Glioblastoma"],"enrollment":{"count":34,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Bevacizumab","otherNames":["Avastin"],"type":"DRUG"},{"name":"PD-L1 t-haNK","otherNames":[],"type":"DRUG"},{"name":"N-803","otherNames":["ALT-803","Anktiva"],"type":"DRUG"},{"name":"Tumor Treating Fields (TTFields, 200 kHz)","otherNames":[],"type":"DEVICE"}],"last_update":"2026-07-01","lead_sponsor":"ImmunityBio, Inc.","official_title":"Open-Label, Single-Arm Phase 2 Study of Nogapendekin Alfa Inbakicept, PD-L1 t-haNK, Bevacizumab and Randomized Phase 2B Study of Nogapendekin Alfa Inbakicept, Bevacizumab, and Tumor Treatment Fields With or Without PD-L1 t-haNK in Participants With Recurrent or Progressive Glioblastoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2029-12-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)","timeFrame":"From beginning of Cycle 1 (each cycle is 28 days) to 30 days after end of treatment study visit."},{"measure":"Incidence of clinically significant changes in comprehensive metabolic panel (CMP)","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Hematology blood panel.","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Urinalysis.","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent treatment Cycle on Days 1 and Day 15 and at the end of treatment study visit."},{"measure":"12-lead Electrocardiogram (ECG)","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and each subsequent Cycle Day1 through to the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Temperature","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Heart Rate","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Respiratory Rate","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Blood Pressure","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit."},{"measure":"Incidence of clinically significant changes in Oxygen Saturation","timeFrame":"From baseline, pre-intervention, Cycle 1 (each cycle is 28 days) and Cycle 2 on days 1, 2 and 15, followed by each subsequent treatment Cycle on Days 1 and 15 and on the end of treatment study visit."},{"measure":"Neurological assessment to grade Immune effector cell-associated neurotoxicity syndrome (ICANS)","timeFrame":"On Cycle 1 (each cycle is 28 days) Day1, Day2, Day 15 and Day16, followed by each subsequent treatment Cycle on Days 1 and 15. Collection stops at the end of treatment study visit."},{"measure":"Safety assessed by Cytokine Levels","timeFrame":"From Cycle 1 (each cycle is 28 days) Day1, Day2, Day 15 and Day16, followed by each subsequent treatment Cycle on Day 1. Collection stops at the end of treatment study visit."}],"references":[],"start_date":{"date":"2024-08-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma","url":"https://clinicaltrials.gov/study/NCT06061809"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/quilt-3-078-nct06061809"}